Insulin resistance is one of the most common—and most overlooked—metabolic conditions in adults over 50. It can quietly damage the heart, brain, kidneys, and liver for years before any standard lab test raises a flag. For health-conscious adults focused on living well, understanding how insulin resistance works and what it sets in motion is one of the most important steps toward long-term prevention.
Why This Matters
Insulin is the hormone that unlocks cells so they can absorb glucose from the bloodstream for energy. When cells stop responding to that signal properly, the pancreas compensates by producing more and more insulin to do the job. That surplus insulin doesn’t just affect blood sugar—it raises triglycerides, promotes belly fat storage, triggers inflammation in blood vessels, and chips away at the body’s ability to perform and recover efficiently.
This condition is far more common than most people realize. Data from national health surveys show that insulin resistance among non-diabetic U.S. adults rose from roughly 25% in 1999–2000 to nearly 38% by 2017–2018 (Wu et al., 2025). Left unaddressed, it reshapes the long-term picture for cardiovascular health, cognitive function, kidney resilience, and even cancer risk.
It Starts Long Before Diabetes—and Hides Behind Normal Labs
Here’s the part that catches many patients off guard: in the early stages of insulin resistance, fasting blood sugar and HbA1c can look completely normal. The pancreas is working overtime to keep glucose in check, masking the problem while damage continues to accumulate in the background.
This explains why many otherwise healthy, active adults feel “metabolically off” even when their doctor says their bloodwork looks fine. Early warning signs tend to be subtle—a slowly expanding waistline, rising triglycerides, a dip in HDL (good cholesterol), or blood pressure creeping upward.
Normal glucose does not rule out insulin resistance. Getting the full picture requires looking at several markers together: waist circumference, triglycerides, HDL, blood pressure, and liver health.
The Ripple Effect on the Body
Insulin resistance isn’t simply a blood sugar problem—it’s a whole-body problem. The chain of effects it sets off touches nearly every major organ system.
Heart and blood vessels. Excess insulin damages the inner lining of blood vessels, raises harmful blood fats, and promotes inflammation and clotting. Even prediabetes—before a diabetes diagnosis—is associated with meaningfully higher cardiovascular risk and mortality compared to normal metabolic function (Huang et al., 2016).
Brain health and memory. The brain depends on insulin to support memory and repair. When insulin resistance extends into the central nervous system, those processes deteriorate—a pattern researchers have begun calling “type 3 diabetes.” Population studies confirm that insulin resistance markers are independently linked to higher rates of both Alzheimer’s disease and vascular dementia (Hong et al., 2021).
Cancer risk. Chronically elevated insulin activates growth-signaling pathways throughout the body, creating biological conditions associated with higher rates of colorectal, pancreatic, breast, kidney, and endometrial cancers (Ling et al., 2020).
Treating insulin resistance as only a precursor to diabetes misses most of the clinical urgency.
Detecting It Requires the Right Tests
Standard lab panels are designed to catch late-stage problems, not early insulin resistance. HbA1c and fasting glucose are valuable, but they can miss years of compensated dysfunction before diagnostic thresholds are crossed. A 75-gram oral glucose tolerance test (OGTT) can reveal how the body handles blood sugar after eating—often catching issues that fasting labs miss entirely. The most complete metabolic picture combines glucose testing with lipid patterns, waist circumference, blood pressure trends, and liver assessment. This broader view is where early intervention becomes possible.
Treatment Works—When It Targets the Right Problem
The good news: insulin resistance responds well to targeted intervention. The landmark Diabetes Prevention Program found that structured lifestyle changes reduced progression from prediabetes to diabetes by 58%—outperforming medication alone (Knowler et al., 2002). Resistance training is especially effective because skeletal muscle is the body’s primary site for glucose disposal. Aerobic exercise improves mitochondrial function and lowers cardiometabolic risk across the board.
When lifestyle changes aren’t enough, medications add meaningful protection. GLP-1–based therapies support significant fat loss and metabolic improvement. SGLT2 inhibitors have demonstrated strong kidney and heart benefits, with large meta-analyses showing roughly a 37% reduction in kidney disease progression and a 23% reduction in cardiovascular death or heart failure hospitalization (Nuffield Department of Population Health Renal Studies Group & SGLT2i Meta-Analysis Consortium, 2022).
A Preventable Problem With a Clear Path Forward
Insulin resistance is not inevitable, and it is not simply a stepping stone to diabetes. It is an active driver of cardiovascular disease, cognitive decline, kidney damage, and cancer risk—one that operates quietly for years before any diagnosis appears. Catching it early, understanding what’s driving it, and building a treatment plan around individual physiology is exactly the kind of work concierge medicine is designed to support—with the time, access, and continuity that prevention requires.
Visit www.naplesconciergehealth.com to learn more or make an appointment.
References
- Huang, Y., Cai, X., Mai, W., Li, M., & Hu, Y. (2016). Association between prediabetes and risk of cardiovascular disease and all cause mortality: Systematic review and meta-analysis. BMJ, 355, i5953. https://doi.org/10.1136/bmj.i5953
- Hong, S., Han, K., & Park, C. Y. (2021). The insulin resistance by triglyceride glucose index and risk for dementia: Population-based study. Alzheimer’s Research & Therapy, 13(1), 9. https://doi.org/10.1186/s13195-020-00758-4
- Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, E. A., Nathan, D. M., & Diabetes Prevention Program Research Group. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 346(6), 393–403. https://doi.org/10.1056/NEJMoa012512
- Ling, S., Brown, K., Miksza, J. K., Howells, L., Morrison, A., Issa, E., Yates, T., Khunti, K., Davies, M. J., & Zaccardi, F. (2020). Association of type 2 diabetes with cancer: A meta-analysis with bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people. Diabetes Care, 43(9), 2313–2322. https://doi.org/10.2337/dc20-0204
- Nuffield Department of Population Health Renal Studies Group & SGLT2i Meta-Analysis Consortium. (2022). Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials. The Lancet, 400(10365), 1788–1801. https://doi.org/10.1016/S0140-6736(22)02074-8
- Wu, C., Ke, Y., & Nianogo, R. A. (2025). Trends in hyperinsulinemia and insulin resistance among nondiabetic US adults, NHANES, 1999–2018. Journal of Clinical Medicine, 14(9), 3215. https://doi.org/10.3390/jcm14093215
